TNFSF13 and systemic lupus erythematosus: In vitro human lymphocyte assays, mouse disease models for arthritis and SLE, and cynomolgus monkey models demonstrated more potent BAFF/APRIL co-antagonism, lymphodepletion (including plasma cells and follicular T-helper cells), suppression of serum immunoglobulins (IgA, IgM, and IgG), decreased titers of antigen-specific antibodies, and reduced lupus disease activity compared to the WT TACI-Fc molecules [79].